Korean J Gastroenterol.  2010 May;55(5):279-295. 10.4166/kjg.2010.55.5.279.

Diagnosis of Gastroesophageal Reflux Disease: a Systematic Review

• Cho YK
• Kim GH
• Kim JH
• Jung HY
• Lee JS
• Kim N
• The Korean Society of Neurogastroenterology and Motility

• KMID: 1718334
• DOI: http://doi.org/10.4166/kjg.2010.55.5.279

Abstract

The prevalence of gastoesophageal reflux disease (GERD) has been rapidly increased in Korea during last 20 years. However, there has been no systematic review regarding this disease. The aim of this article was to provide a review of available diagnostic modalities for GERD. This review includes proton pump inhibitor (PPI) test, endoscopy, ambulatory pH monitoring, impedance pH monitoring, and esophageal manometry in order to provide a basis for the currently applicable recommendations in the diagnosis of GERD in Korea. With weekly heartburn or acid regurgitation, the prevalence of GERD has been reported as 3.4% to 7.9%, indicating an increase of GERD in Korea. As the prevalence of Barrett's esophagus has been reported to be low, the screening endoscopy for Barrett's esophagus is not recommended. Several recent meta-analyses re-evaluated the value of the PPI test in patients with typical GERD symptoms and non-cardiac chest pain. That is, the PPI test has been proven to be a sensitive tool for diagnosing GERD in patients with non-cardiac chest pain and in some preliminary trials regarding extraesophageal manifestations of GERD. Ambulatory pH monitoring of the esophagus helps to confirm gastroesophageal reflux in patients with persistent symptoms (both typical and atypical) in the absence of esophageal mucosal damage, especially when a trial of acid suppression has failed. Impedance pH test is useful in refractory reflux patients with primary complaints of typical GERD symptoms, but this value has not been proved in patients with non-cardiac chest pain or extraesophageal symptoms. This systematic review is targeted to establish the strategy of GERD diagnosis, which is essential for the current clinical practice.

Keyword

Gastoesophageal reflux disease; Diagnosis; Proton pump inhibitor; Ambulatory 24 hr esophageal pH monitoring; Impedance pH test

MeSH Terms

Barrett Esophagus/diagnosis
Esophageal pH Monitoring
Gastroesophageal Reflux/*diagnosis/epidemiology
Humans
Manometry
Proton Pump Inhibitors/metabolism
Risk Factors

Reference

1. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100:190–200.

2. Hirano I, Richter JE. Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007; 102:668–685.

3. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008; 23:8–22.

4. Jung HK. Epidemiology of gastroesophageal reflux disease. The Korean Society of Neurogastroenterology and Motility. ed.Korean Society of Neurogastroenterology and Motility series 9, Gastroesophageal Reflux Disease. Reston: Dae Han Medical Book Publishing Co.;2009. 15.

5. Yi SY, Lee SG, Kim MH, Han DS, Kim JW, Min YI. Epidemiologic study of reflux esophagitis in general health screening people. Korean J Medicine. 1994; 46:514–521.

6. Lee SJ, Song CW, Jeen YT, et al. Prevalence of endoscopic reflux esophagitis among Koreans. J Gastroenterol Hepatol. 2001; 16:373–376.

7. Jeon SG, Son CI, Kim JE, et al. Prevalence of gastroesophageal reflux esophagitis in routine check up subjects. Korean J Med. 2000; 58:145–151.

8. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol. 2005; 100:747–753.

9. Yang SY, Lee OY, Bak YT, et al. Prevalence of gastroesophageal reflux disease symptoms and uninvestigated dyspepsia in Korea: a population-based study. Dig Dis Sci. 2008; 53:188–193.

10. Hwang JK, Kim JH, Hong SG, et al. A prospective multicenter study on the prevalence and symptoms of erosive reflux esophagitis in secondary and tertiary hospitals in Korea. Korean J Gastroenterol. 2009; 53:283–291.

11. Oh JH, Choi MG, Kim HR, et al. Clinical spectrum of endoscopic reflux esophagitis in routine check-up subjects in Korea. Korean J Gastroenterol Motil. 2006; 12:12–18.

12. Kim HY, Kim N, Kim SM, et al. Clinical spectrum and risk factors of erosive and non-erosive GERD in health check-up subjects. Korean J Med. 2006; 71:491–500.

13. Kang MS, Park DI, Oh SY, et al. Abdominal obesity is an independent risk factor for erosive esophagitis in a Korean population. J Gastroenterol Hepatol. 2007; 22:1656–1661.

14. Yoo SS, Lee WH, Ha J, et al. The prevalence of esophageal disorders in the subjects examined for health screening. Korean J Gastroenterol. 2007; 50:306–312.

15. Shim KN, Hong SJ, Sung JK, et al. Clinical spectrum of reflux esophagitis among 25,536 Koreans who underwent a health check-up: a nationwide multicenter prospective, endoscopy-based study. J Clin Gastroenterol. 2009; 43:632–638.

16. Kim N, Lee SW, Cho SI, et al. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther. 2008; 27:173–185.

17. Cho SC, Lee OY, Ha NR, et al. The change in the prevalence of typical gastroesophageal reflux symptoms during the past 5 years in Korea: a population-based study. Korean J Neurogastroenterol Motil. 2008; 14:96–102.

18. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003; 18:595–604.

19. Wu JC. Gastroesophageal reflux disease: an Asian perspective. J Gastroenterol Hepatol. 2008; 23:1785–1793.

20. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009; 44:518–554.

21. Ho KY. Gastroesophageal reflux disease in Asia: a condition in evolution. J Gastroenterol Hepatol. 2008; 23:716–722.

22. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006; 4:398–407.

23. Hu WH, Wong WM, Lam CL, et al. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther. 2002; 16:2081–2088.

24. Watanabe Y, Fujiwara Y, Shiba M, et al. Cigarette smoking and alcohol consumption associated with gastro-oesophageal reflux disease in Japanese men. Scand J Gastroenterol. 2003; 38:807–811.

25. Wang JH, Luo JY, Dong L, Gong J, Tong M. Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi'an of Northwest China. World J Gastroenterol. 2004; 10:1647–1651.

26. Fujiwara Y, Higuchi K, Watanabe Y, et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol. 2005; 20:26–29.

27. Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consec-utive patients. J Am Geriatr Soc. 2006; 54:1537–1542.

28. Chen TS, Chang FY. The prevalence and risk factors of reflux esophagitis among adult Chinese population in Taiwan. J Clin Gastroenterol. 2007; 41:819–822.

29. Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci. 2003; 48:2237–2241.

30. Lee KS, Kim N, Park RY, et al. The role of endoscopy, 24 hour ambulatory esophageal pH monitor and Bernstein test for gastroesophageal reflux disease and its relationship with symptom. Korean J Med. 2006; 70:145–156.

31. Jeong JJ, Choi MG, Cho YS, et al. Chronic gastrointestinal symptoms and quality of life in the Korean population. World J Gastroenterol. 2008; 14:6388–6394.

32. Song HJ, Choi KD, Jung HY, et al. Endoscopic reflux esophagitis in patients with upper abdominal pain-predominant dyspepsia. J Gastroenterol Hepatol. 2007; 22:2217–2221.

33. Neumann H, Monkemuller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett's esophagus. Dig Dis. 2008; 26:243–247.

34. Talley NJ. Overlapping abdominal symptoms: why do GERD and IBS often coexist? Drugs Today (Barc). 2006; 42(suppl B):S3–S8.

35. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009; 79:196–201.

36. Ho KY, Ng WL, Kang JY, Yeoh KG. Gastroesophageal reflux disease is a common cause of noncardiac chest pain in a country with a low prevalence of reflux esophagitis. Dig Dis Sci. 1998; 43:1991–1997.

37. Wong WM, Lam KF, Cheng C, et al. Population based study of noncardiac chest pain in southern Chinese: prevalence, psychosocial factors and health care utilization. World J Gastroenterol. 2004; 10:707–712.

38. Kim JH, Rhee PL, Park EH, Son HJ, Kim JJ, Rhee JC. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. J Gastroenterol Hepatol. 2007; 22:320–325.

39. Choi CW, Kim GH, Song CS, et al. Is obesity associated with gastropharyngeal reflux disease? World J Gastroenterol. 2008; 14:265–271.

40. Chung SJ, Kim D, Park MJ, et al. Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups. Gut. 2008; 57:1360–1365.

41. Lee HL, Eun CS, Lee OY, et al. Association between erosive esophagitis and visceral fat accumulation quantified by abdominal CT scan. J Clin Gastroenterol. 2009; 43:240–243.

42. Moki F, Kusano M, Mizuide M, et al. Association between reflux oesophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther. 2007; 26:1069–1075.

43. Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population. J Clin Gastroenterol. 2008; 42:1074–1079.

44. Wong WM, Lam SK, Hui WM, et al. Longterm prospective follow-up of endoscopic oesophagitis in southern Chinese- prevalence and spectrum of the disease. Aliment Pharmacol Ther. 2002; 16:2037–2042.

45. Kim JH, Rhee PL, Lee JH, et al. Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol. 2007; 22:908–912.

46. Wu JC, Sung JJ, Chan FK, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000; 14:427–432.

47. Yeh C, Hsu CT, Ho AS, Sampliner RE, Fass R. Erosive esophagitis and Barrett's esophagus in Taiwan: a higher frequency than expected. Dig Dis Sci. 1997; 42:702–706.

48. Rosaida MS, Goh KL. Gastro-oesophageal reflux disease, reflux oesophagitis and non-erosive reflux disease in a multi-racial Asian population: a prospective, endoscopy based study. Eur J Gastroenterol Hepatol. 2004; 16:495–501.

49. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999; 26(suppl 5):S2–S8.

50. Kim SJ, Lee JH, Kim BJ, et al. The clinical characteristics and outcomes of Barrett's cancer at a single institution in Korea. Korean J Gastrointest Endoc. 2009; 38:68–74.

51. Peng S, Cui Y, Xiao YL, et al. Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population. Endoscopy. 2009; 41:1011–1017.

52. Okita K, Amano Y, Takahashi Y, et al. Barrett's esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol. 2008; 43:928–934.

53. Kim JY, Kim YS, Jung MK, et al. Prevalence of Barrett's esophagus in Korea. J Gastroenterol Hepatol. 2005; 20:633–636.

54. Lee IS, Choi SC, Shim KN, et al. Prevalence of Barrett's esophagus remains low in the Korean population: nationwide cross-sectional prospective multicenter study. Dig Dis Sci. 2009. [Epub ahead of print].

55. Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett's esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol. 2009; 43:907–914.

56. Gasiorowska A, Fass R. The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol. 2008; 42:867–874.

57. Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94:3122–3125.

58. Wu JC, Chan FK, Ching JY, Leung WK, Lee YT, Sung JJ. Empirical treatment based on ‘typical’ reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc. 2002; 55:461–465.

59. Cho YK, Choi MG, Lim CH, et al. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness. Scand J Gastroenterol. 2010; 45:533–539.

60. Jung HY, Jung KW, Huh KC, et al. Diagnostic significance of one-week esomeprazole treatment in gastroesophageal reflux disease. Korean J Neurogastroenterol Motil. 2008; 14:88–95.

61. Kim JH, Sinn DH, Son HJ, Kim JJ, Rhee JC, Rhee PL. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol. 2009; 24:1504–1509.

62. Sinn DH, Kim JH, Kim S, et al. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther. 2008; 27:1275–1281.

63. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2003; 17:369–377.

64. Ho KY, Gwee KA, Khor CJ, Selamat DS, Wai CT, Yeoh KG. Empirical treatment for the management of patients presenting with uninvestigated reflux symptoms: a prospective study in an Asian primary care population. Aliment Pharmacol Ther. 2005; 21:1313–1320.

65. Mohd H, Qua CS, Wong CH, Azman W, Goh KL. Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population. J Gastroenterol Hepatol. 2009; 24:288–293.

66. Lee ES, Kim N, Lee SH, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 30:154–164.

67. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. A metaanalysis of diagnostic test characteristics. Ann Intern Med. 2004; 40:518–527.

68. Aanen MC Weusten BL, Numans ME, de Wit NJ, Baron A, Smout AJ. Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2006; 24:1377–1384.

69. Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a metaanalysis. Arch Intern Med. 2005; 165:1222–1228.

70. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol. 2005; 100:1226–1232.

71. Tan VP, Wong BC. Non-cardiac chest pain in Asia: time for a consensus. J Gastroenterol Hepatol. 2009; 24:178–179.

72. Wong WM, Wong BC. Noncardiac chest pain: an Asian view. Gastroenterol Clin North Am. 2004; 33:125–133.

73. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for lar-yngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007; 25:385–392.

74. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a metaanalysis of randomized controlled trials. Am J Gastroenterol. 2006; 101:2646–2654.

75. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001; 96:979–983.

76. Ours TM, Kavuru MS, Schilz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic al-gorithm for chronic cough. Am J Gastroenterol. 1999; 94:3131–3138.

77. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specif-ic cough in children and adults. Cochrane Database Syst Rev. 2006; 4:CD004823.

78. Kusano M, Shirai N, Yamaguchi K, et al. It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole – a report from a study with Japanese patients. Dig Dis Sci. 2008; 53:3082–3094.

79. Lee JH, Lee JS, Rhee PL, et al. Interobserver variation in the endoscopic diagnosis of gastroesophageal reflux disease. Kor J Gastrointest Endosc. 2006; 33:197–203.

80. Nakamura T, Shirakawa K, Masuyama H, Sugaya H, Hiraishi H, Terano A. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther. 2005; 21(suppl 2):S19–S26.

81. Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004; 22:221–227.

82. Amano Y, Ishimura N, Furuta K, et al. Interobserver agree-ment on classifying endoscopic diagnoses of nonerosive esophagitis. Endoscopy. 2006; 38:1032–1035.

83. Lee JH, Kim N, Chung IK, et al. Clinical significance of minimal change lesions of the esophagus in a healthy Korean population: a nationwide multicenter prospective study. J Gastroenterol Hepatol. 2008; 23:1153–1157.

84. Zentilin P, Savarino V, Mastracci L, et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005; 100:2299–2306.

85. Reddymasu SC, Sharma P. Advances in endoscopic imaging of the esophagus. Gastroenterol Clin North Am. 2008; 37:763–774.

86. Yoshikawa I, Yamasaki M, Yamasaki T, Kume K, Otsuki M. Lugol chromoendoscopy as a diagnostic tool in so-called endoscopy- negative GERD. Gastrointest Endosc. 2005; 62:698–703.

87. Edebo A, Tam W, Bruno M, et al. Magnification endoscopy for diagnosis of nonerosive reflux disease: a proposal of diagnostic criteria and critical analysis of observer variability. Endoscopy. 2007; 39:195–201.

88. Lee YC, Lin JT, Chiu HM, et al. Intraobserver and interobserver consistency for grading esophagitis with narrow-band imaging. Gastrointest Endosc Clin N Am. 2007; 66:230–236.

89. Meining A, Rösch T, Kiesslich R, Muders M, Sax F, Heldwein W. Inter- and intraobserver variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction. Endoscopy. 2004; 36:160–164.

90. Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007; 133:454–464.

91. Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001; 15:519–524.

92. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005; 3:329–334.

93. Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2005; 3:1083–1088.

94. Frye JW, Vaezi M. Extraesophageal GERD. Gastroenterol Clin North Am. 2008; 37:845–858.

95. Ahmed T, Vaezi MF. The role of pH monitoring in extraesophageal gastroesophageal reflux disease. Gastrointest Endosc Clin N Am. 2005; 15:319–331.

96. An JK, Kim GH, Kim JY, et al. Problem in interpretation of laryngopharyngeal reflux disease accordiong to the location of proximal probe in 24 hour ambulatory esophageal dual probe pH monitoring. Korean J Med. 2002; 62:390–395.

97. Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology. 1995; 109:1575–1582.

98. Noordzij JP, Khidr A, Desper E, Meek RB, Reibel JF, Levine PA. Correlation of pH probe-measured laryngopharyngeal reflux with symptoms and signs of reflux laryngitis. Laryngoscope. 2002; 112:2192–2195.

99. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996; 100:395–405.

100. Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999; 116:1257–1264.

101. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004; 99:1037–1043.

102. Vela M, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001; 120:1599–1606.

103. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol. 2008; 103:2685–2693.

104. Pandolfino J, Richter JE, Ours T, Guardino JM, Chapman J, Kahrias P. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003; 98:740–749.

105. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006; 55:1398–1402.

106. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007; 26:1355–1360.

107. Bredenoord A, Weusten BL, Timmer R, Conchillo JM, Smout AJ. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006; 101:453–459.

108. Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut. 2005; 54:449–454.

109. Anandasabapathy S, Jaffin BW. Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy. Ann Otol Rhinol Laryngol. 2006; 115:563–570.

110. Blondeau K, Dupont LJ, Mertens V, Tack J, Sifrim D. Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. Aliment Pharmacol Ther. 2007; 25:723–732.

111. des Varannes SB, Mion F, Ducrotté P, et al. Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo). Gut. 2005; 54:1682–1686.

112. Pandolfino JE, Zhang Q, Schreiner MA, Ghosh S, Roth MP, Kahrilas PJ. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: why are the numbers so different. Gut. 2005; 54:1687–1692.

113. Bansal A, Wani S, Rastogi A, et al. Impact of measurement of esophageal acid exposure close to the gastroesophageal junction on diagnostic accuracy and event-symptom correlation: a prospective study using wireless dual pH monitoring. Am J Gastroenterol. 2009; 104:2918–2925.

114. Wenner J, Hall M, Hö glund P, Johansson J, Johnsson F, Oberg S. Wireless pH recording immediately above the squamocolumnar junction improves the diagnostic performance of esophageal pH studies. Am J Gastroenterol. 2008; 103:2977–2985.

115. Kim GH, Huh KC, Lee YC, et al. Normal ambulatory 24-hour esophageal pH values in Koreans -a multicenter study. J Korean Med Sci. 2008; 23:954–958.

116. Han DH, Lee JS, Kim YD, et al. Usefulness of multichannel intraluminal impedance-pH metry in patients with suspected GERD presenting with typical or atypical symptoms. Korean J Neurogastroenterol Motil. 2006; 12:25–30.

117. Cho YK, Choi MG, Chang JH, et al. The performance and safety of Bravo esophageal pH monitoring in Korean patients. Korean J Neurogastroenterol Motil. 2007; 13:111–117.